Sentence and cancer type
Showing 601-620 of 873 items.
SentenceCancertype
Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium. None
Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. None
The role of HER-2/neu oncogene and vimentin filaments in the production of the Paget s phenotype. None
Deregulated expression of interferon regulatory factor-1 in oncogene-transformed mouse fibroblasts. None
Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf. None
Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. None
HER-2 oncogene expression is regulated by COX-2 and prostaglandin E2.None
High Nup88 mRNA expression levels correlated with ductal and tubular histology, nuclear grade 3, absence of hormone receptors, expression of c-erb-B2 oncogene and mutant p53 protein, high proliferation, DNA aneuploidy, and axillary node invasion.None
analysis of the proto-oncogenic and mutant forms of the transmembrane region of Neu in micellesNone
Germ-line expression of an oncogenic erbB2 allele confers resistance to erbB2-induced mammary tumorigenesis. None
Increased serum maternal levels of the HER2 oncoprotein p105 ectodomain in preeclampsia. None
Overexpression of HER2/neu oncoprotein in cytologic specimens. None
Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. None
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. None
Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. None
p185HER2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget s disease. None
Tumor suppressor ARF inhibits HER-2/neu-mediated oncogenic growth. None
Expression of epidermal growth factor receptor and c-erbB-2 oncoprotein in trophoblast populations of placenta accreta. None
Amplification of EGFR was found in 10.37% of cases. The analysis revealed a lack of correlation between amplification of the oncogenes and the tumor phenotype.None
Tissue microarray analysis of EGFR and HER2 oncogene copy number alterations in squamous cell carcinoma of the larynx. None